Skip to main content
Registrieren
Springer Medizin Österreich
SUCHE
MENÜ 1 2 3 4
main-content
nach oben

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Wiener klinische Wochenschrift 1-2/2016

01.01.2016 | original article

Serum soluble urokinase-type plasminogen activator receptor and interferon-γ-induced protein 10 levels correlate with significant fibrosis in chronic hepatitis B

verfasst von: MD Dilek Yıldız Sevgi, Assoc. Prof. Banu Bayraktar, MD Alper Gündüz, MD Banu Yılmaz Özgüven, MD Alper Togay, MD Emin Bulut, MD Nuray Uzun, Prof. İlyas Dökmetaş

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 1-2/2016

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Background

Hepatitis B virus (HBV) presents an important public health problem. Liver biopsy is currently the gold standard for assessing the degree of intrahepatic inflammation and for staging liver fibrosis. However, the value of liver biopsies is limited by sampling errors, understaging and interobserver variability in interpretation. There is, therefore, a need to identify novel, non-invasive serologic biomarkers for the development of new predictive models of fibrosis.

Methods

We enrolled patients with chronic hepatitis B infection (CHB) and examined the relationships between serum soluble urokinase plasminogen activator receptor (suPAR) and interferon-induced protein-10 (IP-10), and the results of liver biopsies. Healthy volunteers with normal aminotransferase levels and negative serological results for HBV, hepatitis C virus and human immunodeficiency virus were recruited as controls.

Results

Mean platelet volume, serum suPAR and IP-10 were significantly elevated in patients with CHB compared with controls. Median serum suPAR and IP-10 levels were significantly higher in patients with liver fibrosis compared with patients with mild fibrosis. There was no significant difference in mean platelet volume or aspartate aminotransferase-to-platelet ratio index scores between patients with mild and significant fibrosis.

Conclusion

suPAR and IP-10 were able to distinguish between significant and mild fibrosis with good sensitivity and specificity, and may thus represent useful biomarkers for identifying patients with significant fibrosis.
Vorheriger Artikel Monocytes and monocyte chemoattractant protein 1 (MCP-1) as early predictors of disease outcome in patients with cerebral ischemic stroke
Nächster Artikel Influence of various factors on functional dyspepsia
Literatur
1.
Liver EAFTSOT. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57(1):167–85. CrossRef
2.
Karlmark KR, Wasmuth HE, Trautwein C, Tacke F. Chemokine-directed immune cell infiltration in acute and chronic liver disease. Expert Rev Gastroenterol Hepatol. 2008;2(2):233–42. CrossRefPubMed
3.
Fontana RJ, Goodman ZD, Dienstag JL, Bonkovsky HL, Naishadham D, Sterling RK, et al. Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology. 2008;47(3):789–98. CrossRefPubMed
4.
Castera L. Hepatitis B: are non-invasive markers of liver fibrosis reliable? Liver Int. 2014;34Suppl. 1:91–6. CrossRefPubMed
5.
6.
Zimmermann H, Reuken P, Koch A, Bartneck M, Adams D, Trautwein C, et al. Soluble urokinase plasminogen activator receptor is compartmentally regulated in decompensated cirrhosis and indicates immune activation and short-term mortality. J Intern Med. 2013;274(1):86–100. CrossRefPubMed
7.
Berres M-L, Schlosser B, Berg T, Trautwein C, Wasmuth HE. Soluble urokinase plasminogen activator receptor is associated with progressive liver fibrosis in hepatitis C infection. J Clin Gastroenterol. 2012;46(4):334–8. CrossRefPubMed
8.
Xu Z, Liu Y, Liu L, Li X, Bai S, Rong Y, et al. Association of interferon-gamma induced protein 10 promoter polymorphisms with the disease progression of hepatitis B virus infection in Chinese Han population. PLoS One. 2013;8(9):e72799. PubMedCentralCrossRefPubMed
9.
Ceylan B, Fincanci M, Yardimci C, Eren G, Tozalgan U, Muderrisoglu C, et al. Can mean platelet volume determine the severity of liver fibrosis or inflammation in patients with chronic hepatitis B? Eur J Gastroenterol Hepatol. 2013;25(5):606–12. CrossRefPubMed
10.
Karagoz E, Ulcay A, Tanoglu A, Kara M, Turhan V, Erdem H, et al. Clinical usefulness of mean platelet volume and red blood cell distribution width to platelet ratio for predicting the severity of hepatic fibrosis in chronic hepatitis B virus patients. Eur J Gastroenterol Hepatol. 2014;26(12):1320–4. PubMed
11.
Zeremski M, Dimova R, Brown Q, Jacobson IM, Markatou M, Talal AH. Peripheral CXCR3-associated chemokines as biomarkers of fibrosis in chronic hepatitis C virus infection. J Infect Dis. 2009;200(11):1774–80. CrossRefPubMed
12.
Ceylan B, Mete B, Fincanci M, Aslan T, Akkoyunlu Y, Ozgunes N, et al. A new model using platelet indices to predict liver fibrosis in patients with chronic hepatitis B infection. Wien Klin Wochenschr. 2013;125(15–16):453–60. CrossRefPubMed
13.
14.
Li J, Gordon SC, Rupp LB, Zhang T, Boscarino JA, Vijayadeva V, et al. The validity of serum markers for fibrosis staging in chronic hepatitis B and C. J Viral Hepat. 2014;21(12):930–7. CrossRefPubMed
15.
Andersen ES, Ruhwald M, Moessner B, Christensen PB, Andersen O, Eugen-Olsen J, et al. Twelve potential fibrosis markers to differentiate mild liver fibrosis from cirrhosis in patients infected with chronic hepatitis C genotype 1. Eur J Clin Microbiol Infect Dis. 2011;30(6):761–6. CrossRefPubMed
16.
Zimmermann HW, Koch A, Seidler S, Trautwein C, Tacke F. Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis. Liver Int. 2011;32(3):500–9. PubMed
17.
Fibbi G, D’Alessio S, Pucci M, Cerletti M, Del Rosso M. Growth factor-dependent proliferation and invasion of muscle satellite cells require the cell-associated fibrinolytic system. Biol Chem. 2002;383(1):127–36. CrossRefPubMed
18.
Koch A, Zimmermann HW, Gassler N, Jochum C, Weiskirchen R, Bruensing J, et al. Clinical relevance and cellular source of elevated soluble urokinase plasminogen activator receptor (suPAR) in acute liver failure. Liver Int. 2014;34(9):1330–9. doi: 10.​1111/​liv.​12512. CrossRefPubMed
19.
20.
You CR, Park S-H, Jeong SW, Woo HY, Bae SH, Choi JY, et al. Serum IP-10 levels correlate with the severity of liver histopathology in patients infected with genotype-1 HCV. Gut liver. 2011;5(4):506–12. PubMedCentralCrossRefPubMed
21.
Lee IC, Lin CH, Huang YH, Huo TI, Su CW, Hou MC, et al. IL28B polymorphism correlates with active hepatitis in patients with HBeAg-negative chronic hepatitis B. PLoS One. 2013;8(2):e58071. PubMedCentralCrossRefPubMed
22.
Wang J, Zhao J-H, Wang P-P, Xiang G-J. Expression of CXC chemokine IP-10 in patients with chronic hepatitis B. Hepatobiliary Pancreat Dis Int. 2008;7(1):45–50. PubMed
23.
Mihm S, Schweyer S, Ramadori G. Expression of the chemokine IP-10 correlates with the accumulation of hepatic IFN-γ and IL-18 mRNA in chronic hepatitis C but not in hepatitis B. J Med Virol. 2003;70(4):562–70. CrossRefPubMed
24.
Harvey CE. Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation. J Leukocyte Biol. 2003;74(3):360–9. CrossRefPubMed
25.
Xiao G, Yang J, Yan L. Comparison of Diagnostic accuracy of APRI and FIB-4 for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis. Hepatology. 2015;61(1):292–302. CrossRefPubMed
26.
Assal A, Mackie D, Cooper CL. Transient elastography, APRI, and ultrasound have minimal utility in chronic low-replicative hepatitis B infection. Eur J Gastroenterol Hepatol. 2014;26(9):1010–4. CrossRefPubMed
Metadaten
Titel
Serum soluble urokinase-type plasminogen activator receptor and interferon-γ-induced protein 10 levels correlate with significant fibrosis in chronic hepatitis B
verfasst von
MD Dilek Yıldız Sevgi
Assoc. Prof. Banu Bayraktar
MD Alper Gündüz
MD Banu Yılmaz Özgüven
MD Alper Togay
MD Emin Bulut
MD Nuray Uzun
Prof. İlyas Dökmetaş
Publikationsdatum
01.01.2016
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 1-2/2016
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-015-0886-4

Weitere Artikel der Ausgabe 1-2/2016

Wiener klinische Wochenschrift 1-2/2016 Zur Ausgabe

editorial

Editorial

case report

Repeated sugammadex usage in a patient with multiple sclerosis: a case report

short report

First report of an outbreak of pneumonia caused by Streptococcus pneumoniae serotype 6A

original article

Pollen information consumption as an indicator of pollen allergy burden

original article

Liver metastases from adenocarcinomas of unknown primary site: management and prognosis in 68 consecutive patients

original article

Effects of dilatation types during percutaneous nephrolithotomy for less radiation exposure: a matched-pair pilot study

Version: 0.2148.0